Mon, Jul 28, 2014, 3:13 AM EDT - U.S. Markets open in 6 hrs 17 mins

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Apr 23, 2013 9:30 AM Flag

    ASCO rumor

    $$$$
    COLFAX has posted this on the NZDQ Market Stream...I can't find any verification.

    "$EXEL cabozantinib has updated data from RDT in melanoma and updated bone lesion data in prostate ASCO"
    Still looking...Possibility of a leak?
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Abstract #9094
      Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).
      Adil Daud, MD

    • Is this the real deal? Who knows here? Nobody. However, if you have been following the advice of a few here and established a good core position at a low ACB, and traded on the pattern, I would stick with this disciplined approach. That means, now, you are into cash on the trade side, and long a core position. Maybe the range ticks up a notch. We shall see. But without news, and May swoon just around the corner, cash may be king for trading account. Nothing stopping new folks from establishing a core position, or trading as they see it, but I have seen this gyrate within the ranges and am happy to watch now and see if my core holdings increase in value or once again retrace the bump. Other than some terrible news, which appears highly unlikely, this is a winner for me, and I see, as stated previously the most likely outcome here, huge multi dollar run up, and either a takeover bid above $12 or this going to $30 to $50 within a couple of years. In the meantime all kinds of manipulations, attempts by shorts to get folks to sell and the emotional babbling of those on the wrong side of which ever way its going at the moment. Its a buy for investors, because the reward potential here FAR outweighs the risks at this juncture. IMO

      Sentiment: Strong Buy

    • No leak. The ASCO 2013 itinerary planner went live yesterday. That's where that info is from.

    • mwindsweptfarm@comcast.net mwindsweptfarm Apr 23, 2013 9:57 AM Flag

      Oncologists have been getting very encouraging updates from EXEL about the prostate cancer data. I have been surprised that there are no articles from yahoo contributors. Maybe finally coming out. I have been in since July. Good news will finally explode this stock.

      Sentiment: Strong Buy

 
EXEL
4.19-0.02(-0.48%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.